Dr. Manish Shah on Onartuzumab for Gastroesophageal Adenocarcinoma

Manish A. Shah, MD
Published: Friday, Jan 16, 2015



Manish A. Shah, MD, director of gastrointestinal oncology at Weill Cornell Medical College/New York Presbyterian Hospital, talks about a recent phase II study of mFOLFOX paired with the MET inhibitor onartuzumab for the treatment of metastatic, HER2-negative gastroesophageal adenocarcinoma (GEC). 
 
The study found that the addition of onartuzumab to mFOLFOX6 in metastatic GEC did not improve progression-free survival or overall survival in either an unselected population or in MET-positive patients. 
 
Despite the results, the study did shed some light on the biology of the disease.  The study identified several redundant pathways, including HER2, which can be overexpressed even in MET-over expressing tumors. This may explain why a MET inhibitor did not work in this case, says Shah.  

<<< View more from the 2015 GI Cancer Symposium

 



Manish A. Shah, MD, director of gastrointestinal oncology at Weill Cornell Medical College/New York Presbyterian Hospital, talks about a recent phase II study of mFOLFOX paired with the MET inhibitor onartuzumab for the treatment of metastatic, HER2-negative gastroesophageal adenocarcinoma (GEC). 
 
The study found that the addition of onartuzumab to mFOLFOX6 in metastatic GEC did not improve progression-free survival or overall survival in either an unselected population or in MET-positive patients. 
 
Despite the results, the study did shed some light on the biology of the disease.  The study identified several redundant pathways, including HER2, which can be overexpressed even in MET-over expressing tumors. This may explain why a MET inhibitor did not work in this case, says Shah.  

<<< View more from the 2015 GI Cancer Symposium

 




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x